Lopinavir/ritonavir (ABT-378/r)

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 3, 2002, Pages 315-327

  Qazi, Nadeem A ^a   Morlese, John F ^a   Pozniak, Anton L ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Boosted protease inhibitor; Co formulated; Lopinavir ritonavir; Pharmacokinetic enhancement; Protease inhibitor; Ritonavir

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; ARGENERASE; ATOVAQUONE; CYCLOSPORIN; CYTOCHROME P450 3A4; DELAVIRDINE; DIDANOSINE; DISULFIRAM; EFAVIRENZ; ERGOT DERIVATIVE; FORTAVASE; HYPERICUM PERFORATUM EXTRACT; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; METHADONE; METRONIDAZOLE; NELFINAVIR; NEVIRAPINE; ORAL CONTRACEPTIVE AGENT; PROKINETIC AGENT; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; SAQUINAVIR; STAVUDINE; UNINDEXED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; BIOASSAY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; MORTALITY; NONHUMAN; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION;

CLINICAL TRIALS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PYRIMIDINONES;

EID: 0036192970     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.3.315     Document Type: Article

References (53)

1. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease
2. Human immunodeficiency virus protease inhibitors
3. Single dose pharmacokinetics of ABT-378 in combination with ritonavir
4. Protease inhibitors as anti-HIV agents
5. Impact of pharmacokinetics on treatment success. Redefining the art of HIV management
6. Pharmaco-dynamics of Human Immunodeficiency Virus Type 1 protease inhibitors
7. Multiple-dose pharmacokinetics (PK) of ABT-378/r) in HIV + subjects
8. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction
9. ABT-378/ritonavir (ABT-378/r) in antiretroviral-naïve HIV + patients: 72 weeks
10. Effect of human serum proteins on the antiretroviral activity of ritonavir and ABT-378, potent inhibitors of HIV protease
11. Analysis of safety data from ABT-378/ritonavir (ABT-378/r) in two Phase II clinical trials. Poster presentation
12. Assessment of the pharmacokinetic interaction between ABT-378ritonavir (ABT-378/r) and efavirenz in healthy volunteers and in HIV + subjects
13. Interaction of ABT-378/ritonavir with protease inhibitors in healthy volunteers
14. Steady-state pharmacokinetics of Kaletra (lopinavir/ritonavir 400/100mg b.i.d.) in HIV-infected subjects when taken with food
15. Assessment of the bioequivalence and food effects for liquid and soft elastic capsule co-formulations of ABT-378/ritonavir (ABT-378/r) in healthy subjects
16. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naïve adults with HIV-1 infection: 48-week results
17. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus
18. In vitro metabolism of the HIV-1 protease inhibitor AT-378: Species comparison and metabolite identification
19. ABT-378/ritonavir (ABT-378/r) and efavirenz 24 week safety/efficacy evaluation in multiple PI experienced patients
20. Assessment of the pharmacokinetic interaction between Kaletra™ (lopinavir/ritonavir or ABT-378/r) and nevirapine in HIV-infected pediatric subjects
21. Indinavir concentrations and St. John's wort
22. Pharmacokinetic interactions between Kaletra™ (lopinavir/ritonavir or ABT-378/r) and other non-HIV drugs
23. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients
24. Drug resistance and predicted virological responses to human immunodeficiency virus Type 1 protease inhibitor therapy
25. Multiple dose safety, tolerability and pharmacokinetics of ABT-378 in combination with ritonavir
26. 95 ratio: False precision?
27. Lopinavir/ritonavir (Kaletra) in Antiretroviral-naïve HIV + Patients: 144 Week Follow Up
28. Kaletra™ vs. Nelfinavir in antiretroviral-naïve subjects: Week 60 comparison in a phase III, blinded randomized clinical trail
29. 4T/3TC
30. Durable suppression of HIV + RNA after two years of Kaletra (ABT-378/ritonavir) therapy in single protease inhibitor experienced patients
31. ABT-378/ritonavir (ABT-378/r) and efavirenz: 24-week safety/efficacy evaluation in multiple PI-experienced patients
32. Kaletra (ABT-378/ritonavir) and efavirenz: 48-week safety/efficacy evaluation in multiple PI-experienced patients
33. Kaletra™ (ABT-378/ritonavir) in HIV-infected children at 60 weeks
34. Kaletra™ (ABT-378/ritonavir) in HIV-infected children at 72 weeks
35. Treatment of HIV + subjects co-infected with hepatitis B or C safety and efficacy comparison of Kaletra™ (ABT-378/ritonavir) vs. nelfinavir from a Phase III blinded randomized clinical trial
36. Results from the Kaletra™ early access program
37. Safety of Kaletra: Data from Phase II and Phase III Clinical Trials
38. Use of HIV protease inhibitors as pharmacoenhancers
39. Identification of clinically relevant phenotypic and genotypic breakpoints for ABT-378/r in multiple PI-experienced, NNRTI-naïve patients
40. Interpretation of phenotypic an genotypic resistance to Kaletra™ (ABT-378/ritonavir) in protease inhibitor experienced patients
41. Analysis of mutational patterns associated with response to lopinavir/ritonavir in multiple protease inhibitor-experienced patients
42. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients
43. trough inhibitory quotient predicts virologic response to ABT-378/ritonavir (ABT-378/r) therapy in treatment-experienced patients
44. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
45. In vitro emergence of HIV-1 variants resistant to multiple protease inhibitors
46. Patterns of resistance to lopinavir in protease inhibitor-experienced patients following viral rebound during lopinavir/ritonavir therapy
47. Patterns of protease inhibitor cross-resistance in viral isolates with reduced susceptibility to Lopinavir
48. Lopinavir resistance still not identified in treatment-naïve patients
49. Lack of resistance to Kaletra™ (formerly known as ABT-378/r) observed through 24 weeks of therapy in antiretroviral naïve subjects
50. Absence of resistance to Kaletra (ABT-378/r) observed through 48 weeks of therapy in antiretroviral-naïve subjects
51. In vitro selection and characterization of human immunodeficiency virus Type 1 variants with increased resistance to ABT-378, a novel protease inhibitor
52. Factors Affecting Long-Term Virologic Suppression in Phase II Studies of Lopinavir/ritonavir (LPV/r) in ARV-Naïve or PI-Experienced Patients
53. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents